263 related articles for article (PubMed ID: 31033171)
1. Serial invasive imaging follow-up of the first clinical experience with the Magmaris magnesium bioresorbable scaffold.
Tovar Forero MN; van Zandvoort L; Masdjedi K; Diletti R; Wilschut J; de Jaegere PP; Zijlstra F; Van Mieghem NM; Daemen J
Catheter Cardiovasc Interv; 2020 Feb; 95(2):226-231. PubMed ID: 31033171
[TBL] [Abstract][Full Text] [Related]
2. Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging.
Tenekecioglu E; Serruys PW; Onuma Y; Costa R; Chamié D; Sotomi Y; Yu TB; Abizaid A; Liew HB; Santoso T
JACC Cardiovasc Interv; 2017 Jun; 10(11):1115-1130. PubMed ID: 28527768
[TBL] [Abstract][Full Text] [Related]
3. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Trial Comparing the NeoVas Sirolimus-Eluting Bioresorbable Scaffold and Metallic Everolimus-Eluting Stents.
Han Y; Xu B; Fu G; Wang X; Xu K; Jin C; Tao L; Li L; Hou Y; Su X; Fang Q; Chen L; Liu H; Wang B; Yuan Z; Gao C; Zhou S; Sun Z; Zhao Y; Guan C; Stone GW;
JACC Cardiovasc Interv; 2018 Feb; 11(3):260-272. PubMed ID: 29413240
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of Drug-Eluting Absorbable Metal Scaffold Restenosis: A Serial Optical Coherence Tomography Study.
Ueki Y; Räber L; Otsuka T; Rai H; Losdat S; Windecker S; Garcia-Garcia HM; Landmesser U; Koolen J; Byrne R; Haude M; Joner M
Circ Cardiovasc Interv; 2020 Mar; 13(3):e008657. PubMed ID: 32093514
[TBL] [Abstract][Full Text] [Related]
6. Neointimal Healing Evaluated by Optical Coherence Tomography after Drug-Eluting Absorbable Metal Scaffold Implantation in de novo Native Coronary Lesions: Rationale and Design of the Magmaris-OCT Study.
Karjalainen P; Paana T; Sia J; Nammas W
Cardiology; 2017; 137(4):225-230. PubMed ID: 28467998
[TBL] [Abstract][Full Text] [Related]
7. Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery.
Wu Y; Shen L; Ge L; Wang Q; Qian J; Zhang F; Yao K; Huang D; Chen Y; Ge J
Catheter Cardiovasc Interv; 2016 Mar; 87 Suppl 1():630-7. PubMed ID: 26864162
[TBL] [Abstract][Full Text] [Related]
8. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
[TBL] [Abstract][Full Text] [Related]
9. One-year clinical outcomes and multislice computed tomography angiographic results following implantation of the NeoVas bioresorbable sirolimus-eluting scaffold in patients with single de novo coronary artery lesions.
Wang XZ; Zhang YJ; Fu GS; Jing QM; Xu B; Han YL
Catheter Cardiovasc Interv; 2018 Feb; 91(S1):617-622. PubMed ID: 29392879
[TBL] [Abstract][Full Text] [Related]
10. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
[TBL] [Abstract][Full Text] [Related]
11. Second generation, sirolimus-eluting, bioresorbable Tyrocore scaffold implantation in patients with ST-segment elevation myocardial infarction: Baseline OCT and 30-day clinical outcomes - A FANTOM STEMI pilot study.
Koltowski L; Tomaniak M; Ochijewicz D; Maksym J; Roleder T; Zaleska M; Proniewska K; Opolski G; Kochman J
Catheter Cardiovasc Interv; 2020 Jul; 96(1):E1-E7. PubMed ID: 31343827
[TBL] [Abstract][Full Text] [Related]
12. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
[TBL] [Abstract][Full Text] [Related]
13. Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions.
Abizaid A; Costa RA; Schofer J; Ormiston J; Maeng M; Witzenbichler B; Botelho RV; Costa JR; Chamié D; Abizaid AS; Castro JP; Morrison L; Toyloy S; Bhat V; Yan J; Verheye S
JACC Cardiovasc Interv; 2016 Mar; 9(6):565-74. PubMed ID: 27013155
[TBL] [Abstract][Full Text] [Related]
14. Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation: An Angiographic and Optical Coherence Tomography TROFI II Substudy.
Yamaji K; Brugaletta S; Sabaté M; Iñiguez A; Jensen LO; Cequier A; Hofma SH; Christiansen EH; Suttorp M; van Es GA; Sotomi Y; Onuma Y; Serruys PW; Windecker S; Räber L
JACC Cardiovasc Interv; 2017 Sep; 10(18):1867-1877. PubMed ID: 28935079
[TBL] [Abstract][Full Text] [Related]
15. 6-Month Clinical and Angiographic Outcomes of a Novel Radiopaque Sirolimus-Eluting Bioresorbable Vascular Scaffold: The FANTOM II Study.
Abizaid A; Carrié D; Frey N; Lutz M; Weber-Albers J; Dudek D; Chevalier B; Weng SC; Costa RA; Anderson J; Stone GW;
JACC Cardiovasc Interv; 2017 Sep; 10(18):1832-1838. PubMed ID: 28935075
[TBL] [Abstract][Full Text] [Related]
16. First-in-human evaluation of a novel sirolimus-eluting ultra-high molecular weight APTITUDE bioresorbable scaffold: 9- and 24-month imaging and clinical results of the RENASCENT II trial.
Chieffo A; Khawaja SA; Latib A; Vesga B; Moncada M; Delgado JA; Fonseca J; Testa L; Esposito G; Ferrone M; Cortese B; Maehara A; Granada JF; Colombo A;
EuroIntervention; 2020 Jun; 16(2):e133-e140. PubMed ID: 32149709
[TBL] [Abstract][Full Text] [Related]
17. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of the novel sirolimus-eluting bioresorbable scaffold for the treatment of de novo coronary artery disease: One-year results from a prospective patient-level pooled analysis of NeoVas trials.
Xu K; Fu G; Xu B; Zhou Y; Su X; Liu H; Zhang Z; Yu B; Wang X; Han Y;
Catheter Cardiovasc Interv; 2019 Feb; 93(S1):832-838. PubMed ID: 30888736
[TBL] [Abstract][Full Text] [Related]
19. Randomized Comparison Between Everolimus-Eluting Bioresorbable Scaffold and Metallic Stent: Multimodality Imaging Through 3 Years.
Onuma Y; Honda Y; Asano T; Shiomi H; Kozuma K; Ozaki Y; Namiki A; Yasuda S; Ueno T; Ando K; Furuya J; Hanaoka KI; Tanabe K; Okada K; Kitahara H; Ono M; Kusano H; Rapoza R; Simonton C; Popma JJ; Stone GW; Fitzgerald PJ; Serruys PW; Kimura T
JACC Cardiovasc Interv; 2020 Jan; 13(1):116-127. PubMed ID: 31918929
[TBL] [Abstract][Full Text] [Related]
20. Biodegradable Polymer DES (Ultimaster) vs. Magnesium Bioresorbable Scaffold (BRS Magmaris) in Diabetic Population with NSTE-ACS: A One-Year Clinical Outcome of Two Sirolimus-Eluting Stents.
Rola P; Włodarczak A; Barycki M; Szudrowicz M; Łanocha M; Kulczycki JJ; Turkiewicz K; Woźnica K; Lesiak M; Doroszko A
J Diabetes Res; 2021; 2021():8636050. PubMed ID: 34859105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]